TCGA-43-7657-01A-31R-2125-07
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 68
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- WNT_BETA_CATENIN_SIGNALING+0.430
- UNFOLDED_PROTEIN_RESPONSE+0.350
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.300
- SPERMATOGENESIS+0.260
- HEDGEHOG_SIGNALING+0.250
- HYPOXIA+0.250
- MYC_TARGETS_V1+0.250
- MYC_TARGETS_V2+0.210
- GLYCOLYSIS+0.190
- MTORC1_SIGNALING+0.190
Top 10 suppressed
- IL6_JAK_STAT3_SIGNALING-0.510
- INTERFERON_ALPHA_RESPONSE-0.500
- INTERFERON_GAMMA_RESPONSE-0.490
- ALLOGRAFT_REJECTION-0.480
- INFLAMMATORY_RESPONSE-0.400
- TNFA_SIGNALING_VIA_NFKB-0.400
- COMPLEMENT-0.370
- KRAS_SIGNALING_UP-0.340
- IL2_STAT5_SIGNALING-0.260
- XENOBIOTIC_METABOLISM-0.250
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-77-8128-01A-11R-2247-07 | — | cohortSQ2 | 0.860 |
| 2 | C3L-00445 | — | cohortSQ2 | 0.839 |
| 3 | TCGA-51-4081-01A-01R-1100-07 | — | cohortSQ2 | 0.829 |
| 4 | TCGA-94-A5I6-01A-21R-A27Q-07 | — | cohortSQ2 | 0.827 |
| 5 | TCGA-21-5786-01A-01R-1635-07 | — | cohortSQ1 | 0.814 |
| 6 | add96e53-1114-4364-979b-641665d16629 | — | — | 0.813 |
| 7 | TCGA-B6-A1KF-01A-11R-A13Q-07 | — | E | 0.811 |
| 8 | BS_DS438CXE | high-grade glioma | — | 0.805 |
| 9 | SRR8518411 | — | E | 0.805 |
| 10 | SRR5903551 | — | cohortA1 | 0.804 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| WNT_BETA_CATENIN_SIGNALING | 0.430 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.350 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.300 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.260 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.250 | Inavolisib | — uncovered |
| HYPOXIA | 0.250 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.250 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.210 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.190 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.190 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.180 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.170 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.160 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.150 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.130 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.120 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.110 | Inavolisib | — uncovered |
| MYOGENESIS | 0.100 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.100 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.090 | Cobimetinib | — uncovered |